Scarica l'app Stockscreener
21.54
0.28%
0.06
Dopo l'orario di chiusura:
21.54
Precedente Chiudi:
$21.48
Aprire:
$21.37
Volume 24 ore:
50,806
Relative Volume:
0.38
Capitalizzazione di mercato:
$226.57M
Reddito:
$56.54M
Utile/perdita netta:
$-30.70M
Rapporto P/E:
-55.23
EPS:
-0.39
Flusso di cassa netto:
$-31.05M
1 W Prestazione:
+10.80%
1M Prestazione:
-2.22%
6M Prestazione:
+70.95%
1 anno Prestazione:
+65.69%
Intervallo 1D:
$20.95
$22.06
Intervallo di 1 settimana:
$19.18
$22.82
Portata 52W:
$10.14
$28.42
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Nome
Cidara Therapeutics Inc
Settore
Industria
Telefono
858-752-6170
Indirizzo
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Confronta CDTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
21.54 | 226.57M | 56.54M | -30.70M | -31.05M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-12 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-01-27 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-12-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-08 | Iniziato | Guggenheim | Buy |
| 2024-08-14 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-12-03 | Ripresa | H.C. Wainwright | Buy |
| 2021-09-22 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2021-03-04 | Iniziato | Aegis Capital | Buy |
| 2019-09-04 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2018-07-26 | Iniziato | Citigroup | Buy |
| 2017-04-21 | Iniziato | Raymond James | Strong Buy |
| 2017-04-17 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-12 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-04-11 | Ripresa | Wedbush | Outperform |
| 2017-02-22 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-22 | Aggiornamento | WBB Securities | Sell → Hold |
| 2016-12-21 | Ripresa | Leerink Partners | Outperform |
| 2016-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2016-09-23 | Downgrade | WBB Securities | Hold → Sell |
| 2015-10-09 | Aggiornamento | WBB Securities | Sell → Hold |
| 2015-05-11 | Iniziato | Jefferies | Buy |
| 2015-05-11 | Iniziato | Leerink Partners | Outperform |
| 2015-05-11 | Iniziato | Needham | Buy |
| 2015-05-11 | Iniziato | Wedbush | Outperform |
| 2015-04-23 | Iniziato | WBB Securities | Sell |
Mostra tutto
Cidara Therapeutics Inc Borsa (CDTX) Ultime notizie
Cidara Therapeutics to Report First Quarter 2025 Financial Results on May 8, 2025 - Nasdaq
Cidara Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire
(CDTX) Trading Signals - news.stocktradersdaily.com
Cidara Therapeutics (NASDAQ:CDTX) Upgraded to “Sell” at StockNews.com - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Cidara Therapeutics (NASDAQ:CDTX) - Defense World
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Buy” from Analysts - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Upgraded by StockNews.com to Sell Rating - Defense World
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Increase in Short Interest - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Shares Pass Above 50 Day Moving Average – Time to Sell? - Defense World
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire
New Executive Joins Cidara Therapeutics with $580K+ Stock Compensation Package - Stock Titan
Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Cidara Therapeutics Unveils Latest Innovations at Elite Needham Healthcare Conference - Stock Titan
(CDTX) Investment Analysis - news.stocktradersdaily.com
Elicio Therapeutics Hires CFO From Cidara Therapeutics - MarketWatch
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer - GlobeNewswire
Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know - MSN
Cidara Therapeutics to Participate in World Health - GlobeNewswire
Cidara Therapeutics to present on CD388 at ICAR 2025 - Yahoo Finance
Cidara's Breakthrough H5N1 Flu Drug Takes Center Stage at WHO Emergency Preparedness Meeting - StockTitan
Short Interest in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Increases By 30.7% - Defense World
Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025 - The Manila Times
Cidara Therapeutics Announces Two Presentations on CD388 in - GlobeNewswire
Major Milestone: Cidara's Novel Flu Prevention Drug Completes Massive 5,000-Patient Trial - StockTitan
Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology - GlobeNewswire
Revolutionary Universal Flu Drug Shows Promise Against All Strains, Including Bird Flu - StockTitan
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives $39.14 Average Target Price from Analysts - Defense World
(CDTX) Long Term Investment Analysis - Stock Traders Daily
Citizens Jmp Begins Coverage on Cidara Therapeutics (NASDAQ:CDTX) - Defense World
Cidara therapeutics COO Shane Ward sells shares worth $36,542 By Investing.com - Investing.com Australia
Cidara therapeutics chief scientific officer sells shares worth $38,939 By Investing.com - Investing.com Australia
Cidara therapeutics COO Shane Ward sells shares worth $36,542 - Investing.com India
Cidara therapeutics chief scientific officer sells shares worth $38,939 - Investing.com India
Cidara Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
HC Wainwright Issues Negative Estimate for CDTX Earnings - Defense World
Citizens Capital Markets Initiates Coverage of Cidara Therapeutics (CDTX) with Market Outperform Recommendation - Nasdaq
Cidara stock gains on Citizens' bullish view (CDTX:NASDAQ) - Seeking Alpha
Cidara Therapeutics initiated with an Outperform at Citizens JMP - TipRanks
Cidara stock gains on JMP analyst’s upbeat outlook By Investing.com - Investing.com Canada
FY2029 Earnings Forecast for CDTX Issued By HC Wainwright - Defense World
Buy Rating for Cidara Therapeutics: Promising Potential of CD388 in Influenza Prevention - TipRanks
HC Wainwright Issues Positive Forecast for Cidara Therapeutics (NASDAQ:CDTX) Stock Price - Defense World
Cidara stock price target raised to $35 at H.C. Wainwright By Investing.com - Investing.com Canada
Cidara Therapeutics price target raised to $35 from $24 at H.C. Wainwright - TipRanks
Ed Arce’s Buy Rating for Cidara Therapeutics Driven by Accelerated CD388 Program and Promising Phase 2b NAVIGATE Study Developments - TipRanks
Head-To-Head Analysis: Cidara Therapeutics (NASDAQ:CDTX) vs. Neumora Therapeutics (NASDAQ:NMRA) - Defense World
Cidara Therapeutics Inc Azioni (CDTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):